title: Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity.
abstract: Mixed infections are one of the major therapeutic challenges, as the current strategies have had limited success. One of the most common and widespread conditions of mixed infection is respiratory syncytial virus-mediated pathology of the respiratory tract in children. There is a dire need for the development of novel therapeutic approaches during mixed infections. Therapeutic intravenous immunoglobulin preparations, obtained from plasma pools of healthy donors have been used in immune deficiencies. This study was thus designed to characterize the functional efficacy of RSV-specific antibodies in IVIg. To explore the functional ability of these affinity-purified RSV-specific antibodies, the antibody-dependent and complement dependent cytotoxicity was determined using peripheral cells of healthy donors. This study demonstrates the existence of highly potent RSV-specific antibodies in IVIg preparations and provides the basis for the use of IVIg as broad-spectrum protective shield to RSV-infected children during mixed infections.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale, Unité 872, Paris, France.
authors.forename: Nimesh
authors.initials: N
authors.lastname: Gupta
authors.forename: Jerome
authors.initials: J
authors.lastname: LeGoff
authors.forename: Soulaima
authors.initials: S
authors.lastname: Chamat
authors.forename: Severine
authors.initials: S
authors.lastname: Mercier-Delarue
authors.forename: Olivier
authors.initials: O
authors.lastname: Touzelet
authors.forename: Ultan F
authors.initials: UF
authors.lastname: Power
authors.forename: Michel D
authors.initials: MD
authors.lastname: Kazatchkine
authors.forename: Francois
authors.initials: F
authors.lastname: Simon
authors.forename: Sebastien
authors.initials: S
authors.lastname: Lacroix-Desmazes
authors.forename: Jagadeesh
authors.initials: J
authors.lastname: Bayry
authors.forename: Srinivas V
authors.initials: SV
authors.lastname: Kaveri
mesh_terms: D000914:Antibodies, Viral / Q000276:immunology* / Q000302:isolation & purification*; D000920:Antibody-Dependent Cell Cytotoxicity; D002460:Cell Line; D002648:Child; D003165:Complement System Proteins / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000302:isolation & purification; D016756:Immunoglobulins, Intravenous; D012136:Respiratory Syncytial Viruses / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D003165:Complement System Proteins
references.citation: J Immunol. 2009 Nov 15;183(10):6338-45
references.pmid: 19841167
references.citation: PLoS One. 2012;7(12):e51485
references.pmid: 23300550
references.citation: J Gen Virol. 2009 May;90(Pt 5):1119-1123
references.pmid: 19264600
references.citation: Clin Diagn Lab Immunol. 1998 Jan;5(1):98-104
references.pmid: 9455889
references.citation: J Gen Virol. 1987 Sep;68 ( Pt 9):2521-4
references.pmid: 3655746
references.citation: J Infect Dis. 1994 Jun;169(6):1368-73
references.pmid: 8195619
references.citation: Clin Vaccine Immunol. 2012 Apr;19(4):623-5
references.pmid: 22379062
references.citation: N Engl J Med. 1993 Nov 18;329(21):1524-30
references.pmid: 8413475
references.citation: J Infect Dis. 1995 Aug;172(2):389-94
references.pmid: 7622882
references.citation: Nat Rev Drug Discov. 2011 Feb;10(2):101-11
references.pmid: 21283105
references.citation: Vox Sang. 2009 Nov;97(4):348-54
references.pmid: 19656348
references.citation: Nat Immunol. 2001 Aug;2(8):732-8
references.pmid: 11477410
references.citation: J Microbiol Immunol Infect. 2011 Jun;44(3):184-90
references.pmid: 21524612
references.citation: Clin Diagn Lab Immunol. 1994 May;1(3):342-7
references.pmid: 7496973
references.citation: N Engl J Med. 2001 Sep 6;345(10):747-55
references.pmid: 11547745
references.citation: Trends Pharmacol Sci. 2004 Jun;25(6):306-10
references.pmid: 15165745
references.citation: J Infect Dis. 2009 Aug 1;200(3):439-47
references.pmid: 19545210
references.citation: Infect Immun. 1982 Aug;37(2):492-8
references.pmid: 7118247
references.citation: Transfus Med. 2002 Apr;12(2):133-9
references.pmid: 11982967
references.citation: N Engl J Med. 2001 Jun 21;344(25):1917-28
references.pmid: 11419430
references.citation: Viral Immunol. 2012 Jun;25(3):193-203
references.pmid: 22551066
references.citation: J Infect Dis. 2003 Nov 15;188(10):1610; author reply 1610-1
references.pmid: 14624389
references.citation: J Virol. 2012 Oct;86(19):10880-4
references.pmid: 22837211
references.citation: Nat Rev Rheumatol. 2011 Jun;7(6):349-59
references.pmid: 21556030
references.citation: Curr Opin Pediatr. 2001 Jun;13(3):256-60
references.pmid: 11389361
references.citation: J Infect Dis. 2003 Jul 1;188(1):5-12
references.pmid: 12825165